New drug duo aims to outsmart tough lymphoma

NCT ID NCT06536049

Recruiting now Disease control Sponsor: Yazeed Sawalha Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This trial tests a combination of two drugs, epcoritamab and ibrutinib, for people with aggressive B-cell non-Hodgkin lymphoma that has returned or not responded to treatment. Epcoritamab helps immune cells attack lymphoma cells, while ibrutinib blocks signals that help cancer cells grow. The study will enroll 38 participants to find the best dose and see how well the combination works.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: epcoritamab and ibrutinib
What this could lead to: If successful, this combination could offer a new treatment option for patients with aggressive B-cell lymphoma that has not responded to prior therapy.
What could go wrong: This is an early-phase trial with only 38 participants, so results may not apply broadly. Side effects like cytokine release syndrome are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECURRENT DIFFUSE LARGE B-CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diffuse large B-cell lymphoma follicular lymphoma high grade B-cell lymphoma high grade B-cell lymphoma with MYC and/ or BCL2 and/or BCL6 rearrangement non-Hodgkin lymphoma primary mediastinal large B-cell lymphoma relapsed/refractory diffuse large B-cell lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RECURRENT DIFFUSE LARGE B-CELL LYMPHOMA RECURRENT GRADE 3B FOLLICULAR LYMPHOMA RECURRENT HIGH GRADE B-CELL LYMPHOMA WITH MYC AND BCL2 OR BCL6 REARRANGEMENTS RECURRENT HIGH GRADE B-CELL LYMPHOMA WITH MYC, BCL2, AND BCL6 REARRANGEMENTS RECURRENT HIGH GRADE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED RECURRENT PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA RECURRENT TRANSFORMED NON-HODGKIN LYMPHOMA REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA REFRACTORY GRADE 3B FOLLICULAR LYMPHOMA REFRACTORY HIGH GRADE B-CELL LYMPHOMA WITH MYC AND BCL2 OR BCL6 REARRANGEMENTS REFRACTORY HIGH GRADE B-CELL LYMPHOMA WITH MYC, BCL2, AND BCL6 REARRANGEMENTS REFRACTORY HIGH GRADE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED REFRACTORY PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA REFRACTORY TRANSFORMED NON-HODGKIN LYMPHOMA

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Ohio State University Comprehensive Cancer Center
RECRUITING

Columbus, Ohio, 43210, United States
University of Minnesota/Masonic Cancer Center
RECRUITING

Minneapolis, Minnesota, 55455, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.